Clinical Benefits of Memantine Treatment for Alzheimer's Disease in the Okayama Memantine Study II (OMS II)

Kosuke Matsuzono, Toru Yamashita, Yasuyuki Ohta, Nozomi Hishikawa, Makoto Koike, Kota Sato, Syoichiro Kono, Kentaro Deguchi, Yumiko Nakano, Koji Abe

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The clinical benefits of memantine, depending on the baseline cognitive and affective conditions in realworld dementia clinics, have not been completely examined. We performed the "Okayama Memantine Study II (OMS II)" to retrospectively evaluate the clinical effects of memantine monotherapy (n = 38) in Alzheimer's disease (AD) patients using seven batteries to assess dementia at the baseline, at 3, 6, and 12 months. Additionally, we divided 163 AD patients treated with memantine into two subgroups depending on the baseline cognitive score of the Mini-Mental State Examination (MMSE): the MMSE

Original languageEnglish
Pages (from-to)487-493
Number of pages7
JournalJournal of Alzheimer's Disease
Volume47
Issue number2
DOIs
Publication statusPublished - Jul 24 2015

Fingerprint

Memantine
Alzheimer Disease
Dementia
Therapeutics

Keywords

  • Alzheimer's disease
  • behavioral and psychological symptoms of dementia
  • memantine
  • Mini-Mental State Examination
  • monotherapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Clinical Benefits of Memantine Treatment for Alzheimer's Disease in the Okayama Memantine Study II (OMS II). / Matsuzono, Kosuke; Yamashita, Toru; Ohta, Yasuyuki; Hishikawa, Nozomi; Koike, Makoto; Sato, Kota; Kono, Syoichiro; Deguchi, Kentaro; Nakano, Yumiko; Abe, Koji.

In: Journal of Alzheimer's Disease, Vol. 47, No. 2, 24.07.2015, p. 487-493.

Research output: Contribution to journalArticle

Matsuzono, Kosuke ; Yamashita, Toru ; Ohta, Yasuyuki ; Hishikawa, Nozomi ; Koike, Makoto ; Sato, Kota ; Kono, Syoichiro ; Deguchi, Kentaro ; Nakano, Yumiko ; Abe, Koji. / Clinical Benefits of Memantine Treatment for Alzheimer's Disease in the Okayama Memantine Study II (OMS II). In: Journal of Alzheimer's Disease. 2015 ; Vol. 47, No. 2. pp. 487-493.
@article{791fc1fde51b4a24a07160319dbbf066,
title = "Clinical Benefits of Memantine Treatment for Alzheimer's Disease in the Okayama Memantine Study II (OMS II)",
abstract = "The clinical benefits of memantine, depending on the baseline cognitive and affective conditions in realworld dementia clinics, have not been completely examined. We performed the {"}Okayama Memantine Study II (OMS II){"} to retrospectively evaluate the clinical effects of memantine monotherapy (n = 38) in Alzheimer's disease (AD) patients using seven batteries to assess dementia at the baseline, at 3, 6, and 12 months. Additionally, we divided 163 AD patients treated with memantine into two subgroups depending on the baseline cognitive score of the Mini-Mental State Examination (MMSE): the MMSE",
keywords = "Alzheimer's disease, behavioral and psychological symptoms of dementia, memantine, Mini-Mental State Examination, monotherapy",
author = "Kosuke Matsuzono and Toru Yamashita and Yasuyuki Ohta and Nozomi Hishikawa and Makoto Koike and Kota Sato and Syoichiro Kono and Kentaro Deguchi and Yumiko Nakano and Koji Abe",
year = "2015",
month = "7",
day = "24",
doi = "10.3233/JAD-150094",
language = "English",
volume = "47",
pages = "487--493",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Clinical Benefits of Memantine Treatment for Alzheimer's Disease in the Okayama Memantine Study II (OMS II)

AU - Matsuzono, Kosuke

AU - Yamashita, Toru

AU - Ohta, Yasuyuki

AU - Hishikawa, Nozomi

AU - Koike, Makoto

AU - Sato, Kota

AU - Kono, Syoichiro

AU - Deguchi, Kentaro

AU - Nakano, Yumiko

AU - Abe, Koji

PY - 2015/7/24

Y1 - 2015/7/24

N2 - The clinical benefits of memantine, depending on the baseline cognitive and affective conditions in realworld dementia clinics, have not been completely examined. We performed the "Okayama Memantine Study II (OMS II)" to retrospectively evaluate the clinical effects of memantine monotherapy (n = 38) in Alzheimer's disease (AD) patients using seven batteries to assess dementia at the baseline, at 3, 6, and 12 months. Additionally, we divided 163 AD patients treated with memantine into two subgroups depending on the baseline cognitive score of the Mini-Mental State Examination (MMSE): the MMSE

AB - The clinical benefits of memantine, depending on the baseline cognitive and affective conditions in realworld dementia clinics, have not been completely examined. We performed the "Okayama Memantine Study II (OMS II)" to retrospectively evaluate the clinical effects of memantine monotherapy (n = 38) in Alzheimer's disease (AD) patients using seven batteries to assess dementia at the baseline, at 3, 6, and 12 months. Additionally, we divided 163 AD patients treated with memantine into two subgroups depending on the baseline cognitive score of the Mini-Mental State Examination (MMSE): the MMSE

KW - Alzheimer's disease

KW - behavioral and psychological symptoms of dementia

KW - memantine

KW - Mini-Mental State Examination

KW - monotherapy

UR - http://www.scopus.com/inward/record.url?scp=84938701533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938701533&partnerID=8YFLogxK

U2 - 10.3233/JAD-150094

DO - 10.3233/JAD-150094

M3 - Article

C2 - 26401570

AN - SCOPUS:84938701533

VL - 47

SP - 487

EP - 493

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -